API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 6 sources · 5 days · First seen · Last updated

US oncology treatment and practice developments

Overview

The landscape of oncology in the United States is characterized by expanding therapeutic options alongside practical challenges in clinical implementation and patient access.

Clinicians have noted that while new regimens for metastatic colorectal cancer and HER2-positive breast cancer show improved survival rates, there is a disconnect between clinical trial populations and the more fragile patients seen in practice. In Florida, providers reported that despite an increase in oncology and hematology approvals, demographic shifts and payer restrictions are creating barriers to care. Managing side effects, such as interstitial lung disease, remains a priority for those using newer targeted therapies.

Recent regulatory developments include the FDA granting accelerated approval to dostarlimab-gxly for certain locally advanced rectal cancer patients, potentially allowing some to avoid traditional chemotherapy, radiation, or surgery. Additionally, tucatinib has seen expanded use in maintenance treatments for HER2-positive breast cancer. Beyond pharmaceutical advancements, medical professionals are also discussing the implementation of radiation oncology service lines in community practices, specifically regarding the use of low-dose radiation for benign conditions.

Entities

AstraZeneca · Tampa General Hospital · Novartis · Heath Skinner · FDA

Timeline

  1. [HEALTH] 3 sources
    Oncology developments: New FDA approvals and radiation oncology service implementation

    New FDA approvals for rectal and breast cancer treatments are emerging alongside guidance on implementing radiation oncology service lines in community medical practices.

  2. [HEALTH] 5 sources
    Oncology clinicians discuss evolving cancer treatment landscapes

    Oncology experts are addressing the balance between a surge in new cancer therapy approvals and the practical challenges of managing treatment toxicities and ensuring patient access to care.

Sources

cancernetwork.com · news.usask.ca · oncnursingnews.com · pharmacytimes.com · spotonalabama.com · timelines.issarice.com